https://www.biopharmawatch.com/news/OLMA/slotexpress-welcome-bonus-wagering-requirements BiopharmaWatch en 2026-07-25T15:47:33.000Z SlotExpress Welcome Bonus Wagering Requirements Explained https://www.biopharmawatch.com/news/OLMA/pixelbet-welcome-bonus-sweden-conditions BiopharmaWatch en 2026-07-25T15:30:23.000Z Pixelbet Welcome Bonus In Sweden And Its Conditions https://www.biopharmawatch.com/news/OLMA/gamdom-login-verification-issues-uk BiopharmaWatch en 2026-07-25T14:17:25.000Z Resolving Gamdom Login And Verification Issues In The UK https://www.biopharmawatch.com/news/OLMA/gamdom-login-verification-issues-uk BiopharmaWatch en 2026-07-25T14:17:25.000Z Resolving Gamdom Login And Verification Issues In The UK https://www.biopharmawatch.com/news/OLMA/delicious-slots-login-problems-uk-fixes-solutions BiopharmaWatch en 2026-07-25T14:14:09.000Z Delicious Slots Login Problems In The United Kingdom: Fixes And Solutions https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-2026-annual-meeting-stockholders BiopharmaWatch en 2026-07-24T21:05:45.922Z Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders https://www.biopharmawatch.com/news/HCSG/armor-health-lucas-county-corrections-center BiopharmaWatch en 2026-07-24T21:03:00.000Z Armor Health Selected to Provide Healthcare Services for the Lucas County Corrections Center in Toledo, Ohio https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-agm-september-2026 BiopharmaWatch en 2026-07-24T21:00:00.000Z NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026 https://www.biopharmawatch.com/news/HCSG/pennyroyal-healthcare-data-incident-notice BiopharmaWatch en 2026-07-24T21:00:00.000Z Pennyroyal Healthcare Services Provides Notice of Data Incident https://www.biopharmawatch.com/news/MDXH/mdxhealth-nasdaq-notification-minimum-market-value-deficiency BiopharmaWatch en 2026-07-24T20:59:00.000Z Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency https://www.biopharmawatch.com/news/IRMD/iradimed-q2-2026-financial-results-conference-call BiopharmaWatch en 2026-07-24T20:15:00.000Z IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026 https://www.biopharmawatch.com/news/LFMD/lifemd-report-q2-2026-financial-results BiopharmaWatch en 2026-07-24T20:12:04.070Z LifeMD to Report Second Quarter 2026 Financial Results on August 5 https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-shareholders-approve-proposals-growth BiopharmaWatch en 2026-07-24T20:05:00.000Z VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth https://www.biopharmawatch.com/news/BRKR/bruker-q2-2026-earnings-release-webcast BiopharmaWatch en 2026-07-24T20:01:00.000Z Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-rad204-phase-1-trial-update BiopharmaWatch en 2026-07-24T19:45:46.000Z Radiopharm Theranostics Achieves Confirmed Durable PartialResponse in Ongoing Phase 1 Trial of RAD204 in Patients withAdvanced Solid Tumors Post-Immunotherapy https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-lytenava-fda-approval-wet-amd BiopharmaWatch en 2026-07-24T18:40:00.000Z Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-menarini-chmp-positive-opinion-ubeslo BiopharmaWatch en 2026-07-24T16:57:00.000Z NewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo® https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-erna-101-cancer-therapy BiopharmaWatch en 2026-07-24T13:20:00.000Z Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies https://www.biopharmawatch.com/news/ALC/aravind-alcon-global-retinal-training-center-coimbatore BiopharmaWatch en 2026-07-24T13:20:00.000Z Aravind Eye Care System y Alcon inauguran un centro global para la formación en retina en Coimbatore, India https://www.biopharmawatch.com/news/ALC/aravind-alcon-global-centre-coimbatore BiopharmaWatch en 2026-07-24T13:12:00.000Z Aravind Eye Care System und Alcon eröffnen in Coimbatore, Indien, ein globales Kompetenzzentrum für die Ausbildung im Bereich Netzhautmedizin https://www.biopharmawatch.com/news/HYFT/mindwalk-reveals-reefIQ-ai-drug-discovery BiopharmaWatch en 2026-07-24T13:10:00.000Z A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed https://www.biopharmawatch.com/news/SGRY/surgery-partners-agreement-sale-idaho-falls-facilities BiopharmaWatch en 2026-07-24T13:00:00.000Z Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transaction https://www.biopharmawatch.com/news/AMIX/autonomix-medical-renal-nerve-sensing-study BiopharmaWatch en 2026-07-24T12:47:00.000Z Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study https://www.biopharmawatch.com/news/VIR/vir-biotechnology-cfo-transition BiopharmaWatch en 2026-07-24T12:30:00.000Z Vir Biotechnology Announces Chief Financial Officer Transition https://www.biopharmawatch.com/news/RDGT/ridgetech-leadership-zhejiang-biomedical-association BiopharmaWatch en 2026-07-24T12:30:00.000Z Ridgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association https://www.biopharmawatch.com/news/IMMP/immutep-abstract-esmo-congress-2026 BiopharmaWatch en 2026-07-24T12:00:00.000Z Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/OGN/organon-vtama-phase-3-data-improvements-eczema BiopharmaWatch en 2026-07-24T12:00:00.000Z New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-starlight-1-trial-update BiopharmaWatch en 2026-07-24T12:00:00.000Z Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-chmp-opinion-obicetrapib BiopharmaWatch en 2026-07-24T12:00:00.000Z NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) https://www.biopharmawatch.com/news/PHGE/biomx-zorronet-european-collaborations BiopharmaWatch en 2026-07-24T11:45:00.000Z BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe https://www.biopharmawatch.com/news/HCA/hca-healthcare-reports-q2-2026-results BiopharmaWatch en 2026-07-24T11:30:00.000Z HCA Healthcare Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/CGC/canopy-growth-q1-2027-financial-results-report BiopharmaWatch en 2026-07-24T11:30:00.000Z Canopy Growth to Report First Quarter Fiscal 2027 Financial Results on August 7, 2026 https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-arimoclomol-npc-regulatory-update BiopharmaWatch en 2026-07-24T11:30:00.000Z Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-us4-1-million-offering BiopharmaWatch en 2026-07-24T11:15:00.000Z Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan https://www.biopharmawatch.com/news/QDEL/quidelortho-report-q2-2026-financial-results BiopharmaWatch en 2026-07-24T11:00:00.000Z QuidelOrtho to Report Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-second-quarter-2026-results BiopharmaWatch en 2026-07-24T10:50:00.000Z ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET https://www.biopharmawatch.com/news/MRK/merck-alimatravir-access-plans-hiv-prevention BiopharmaWatch en 2026-07-24T10:45:00.000Z Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development https://www.biopharmawatch.com/news/ALC/aravind-alcon-global-centre-excellence-retina-training BiopharmaWatch en 2026-07-24T10:37:00.000Z Aravind Eye Care System and Alcon Launch Global Centre of Excellence for Retina Training in Coimbatore, India https://www.biopharmawatch.com/news/MNKD/mannkind-announces-50-million-private-placement BiopharmaWatch en 2026-07-24T10:35:00.000Z MannKind Announces $50 Million Private Placement https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-fda-approval BiopharmaWatch en 2026-07-24T10:30:00.000Z MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease https://www.biopharmawatch.com/news/GILD/chmp-recommends-gilead-trodelvy-keytruda-tnbc BiopharmaWatch en 2026-07-24T10:26:00.000Z CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer https://www.biopharmawatch.com/news/SER/serina-therapeutics-btig-conference-2026 BiopharmaWatch en 2026-07-24T10:00:00.000Z Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference https://www.biopharmawatch.com/news/SNY/sanofi-discontinues-amlitelimab-atopic-dermatitis BiopharmaWatch en 2026-07-24T05:30:00.000Z Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-collaboration-success BiopharmaWatch en 2026-07-24T03:29:17.000Z YD Bio 攜手愛立基生醫圓滿完成 2026 亞洲生技大展展出，展示眼科、腫瘤診斷與臨床服務領域創新成果 https://www.biopharmawatch.com/news/TLX/tlx400-tx-encouraging-disease-control-mtc BiopharmaWatch en 2026-07-23T23:49:33.000Z EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-5-million-offering BiopharmaWatch en 2026-07-23T22:49:00.000Z China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-2026-annual-report BiopharmaWatch en 2026-07-23T21:15:00.000Z HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q2-2026-results-announcement BiopharmaWatch en 2026-07-23T21:15:00.000Z Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026 https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q2-2026-financial-results BiopharmaWatch en 2026-07-23T21:00:00.000Z Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-merger-update-cash-dividend BiopharmaWatch en 2026-07-23T20:33:00.152Z VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience https://www.biopharmawatch.com/news/ALGN/align-technology-innovations-invisalign-treatment-planning BiopharmaWatch en 2026-07-23T20:30:00.000Z Align Technology Announces New Innovations to Advance Invisalign® Treatment Planning and Enhance Patient Engagement Through Its Integrated Align™ Digital Platform https://www.biopharmawatch.com/news/CVRX/cvrx-second-quarter-2026-results-conference-call BiopharmaWatch en 2026-07-23T20:30:00.000Z CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026